Medical Developments International Full Year 2024 Earnings: Misses Expectations

Medical Developments International (ASX:MVP) Full Year 2024 Results

Key Financial Results

• Revenue: AU$33.1m (up 2.5% from FY 2023).
• Net loss: AU$41.0m (loss widened by AU$35.4m from FY 2023).
• AU$0.47 loss per share (further deteriorated from AU$0.067 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medical Developments International Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 39% growth forecast for the Pharmaceuticals industry in Australia.

Performance of the Australian Pharmaceuticals industry.

The company's shares are up 2.2% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Medical Developments International you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.